Sterile inflammation in hepatic ischemia/reperfusion injury: Present concepts and potential therapeutics

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 3, 2013, Pages 394-400

  Van Golen, Rowan F ^a   Reiniers, Megan J ^a   Olthof, Pim B ^a   van Gulik, Thomas M ^a   Heger, Michal ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Ischemia reperfusion; Liver immunobiology; Liver surgery; Liver transplantation; Oxidative and nitrosative stress

Indexed keywords

ANTIGEN; DAMAGE ASSOCIATED MOLECULAR PATTERN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 17; NILOTINIB; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; CONFORMATION; CYTOKINE PRODUCTION; HUMAN; INFLAMMATION; LEUKOCYTE; LIVER FUNCTION; LIVER ISCHEMIA; MONOCYTE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 84874357948     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12072     Document Type: Article

References (101)

1. van Golen RF, van Gulik TM, Heger M. The sterile immune response during hepatic ischemia/reperfusion. Cytokine Growth Factor Rev. 2012; 23: 69-84.
2. van Golen RF, van Gulik TM, Heger M. Mechanistic overview of reactive species-induced degradation of the endothelial glycocalyx during hepatic ischemia/reperfusion injury. Free Radic. Biol. Med. 2012; 52: 1382-1402.
3. Chan AT, Giovannucci EL. Primary prevention of colorectal cancer. Gastroenterology 2010; 138: 2029-43.e10.
4. El-Serag HB. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365: 1118-1127.
5. Veteläinen R, van Vliet A, Gouma DJ, van Gulik TM. Steatosis as a risk factor in liver surgery. Ann. Surg. 2007; 245: 20-30.
6. Renz JF, Kin C, Kinkhabwala M etal. Utilization of extended donor criteria liver allografts maximizes donor use and patient access to liver transplantation. Ann. Surg. 2005; 242: 556-563.
7. Merion RM. It is time to look inward. Liver Transpl. 2011; 17: 1125-1126.
8. Bahde R, Spiegel HU. Hepatic ischaemia-reperfusion injury from bench to bedside. Br. J. Surg. 2010; 97: 1461-1475.
9. Gurusamy KS, Kumar Y, Pamecha V, Sharma D, Davidson BR. Ischaemic pre-conditioning for elective liver resections performed under vascular occlusion. Cochrane Database Syst. Rev. 2009; (1): CD007629.
10. Gurusamy KS, Sheth H, Kumar Y, Sharma D, Davidson BR. Methods of vascular occlusion for elective liver resections. Cochrane Database Syst. Rev. 2009; (1): CD007632.
11. Singal AK, Jampana SC, Weinman SA. Antioxidants as therapeutic agents for liver disease. Liver Int. 2011; 31: 1432-1448.
12. Abu-Amara M, Gurusamy KS, Glantzounis G, Fuller B, Davidson BR. Pharmacological interventions for ischaemia reperfusion injury in liver resection surgery performed under vascular control. Cochrane Database Syst. Rev. 2009; (4): CD008154.
13. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am. J. Physiol. 1991; 260 (Pt 1): G355-362.
14. Mukhopadhyay P, Horváth B, Zsengeller Z etal. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants. Free Radic. Biol. Med. 2012; 53: 1123-1138.
15. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008; 8: 279-289.
16. Huang H, Evankovich J, Yan W etal. Endogenous histones function as alarmins in sterile inflammatory liver injury through toll-like receptor 9. Hepatology 2011; 54: 999-1008.
17. Bamboat ZM, Ocuin LM, Balachandran VP, Obaid H, Plitas G, Dematteo RP. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J. Clin. Invest. 2010; 120: 559-569.
18. McDonald B, Pittman K, Menezes GB etal. Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science 2010; 330: 362-366.
19. Ogiku M, Kono H, Hara M, Tsuchiya M, Fujii H. Glycyrrhizin prevents liver injury by inhibition of high-mobility group box 1 production by Kupffer cells after ischemia-reperfusion in rats. J. Pharmacol. Exp. Ther. 2011; 339: 93-98.
20. Hoque R, Sohail MA, Salhanick S etal. P2X7 receptor-mediated purinergic signaling promotes liver injury in acetaminophen hepatotoxicity in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2012; 302: G1171-1179.
21. Zeng S, Dun H, Ippagunta N etal. Receptor for advanced glycation end product (RAGE)-dependent modulation of early growth response-1 in hepatic ischemia/reperfusion injury. J. Hepatol. 2009; 50: 929-936.
22. Tsung A, Hoffman RA, Izuishi K etal. Hepatic ischemia/reperfusion injury involves functional TLR4 signaling in nonparenchymal cells. J. Immunol. 2005; 175: 7661-7668.
23. Wu J, Meng Z, Jiang M etal. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Immunology 2010; 129: 363-374.
24. Yamaguchi Y, Matsumura F, Takeya M etal. Monocyte chemoattractant protein-1 enhances expression of intercellular adhesion molecule-1 following ischemia-reperfusion of the liver in rats. Hepatology 1998; 27: 727-734.
25. Ma W, Wang ZR, Shi L, Yuan Y. Expression of macrophage inflammatory protein-1alpha in Kupffer cells following liver ischemia or reperfusion injury in rats. World J. Gastroenterol. 2006; 12: 3854-3858.
26. Hisama N, Yamaguchi Y, Ishiko T etal. Kupffer cell production of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion injury in rats. Hepatology 1996; 24: 1193-1198.
27. Sakai N, Van Sweringen HL, Belizaire RM etal. IL-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells. J. Gastroenterol. Hepatol. 2012; 27: 1609-1616.
28. Le Moine O, Louis H, Demols A etal. Cold liver ischemia-reperfusion injury critically depends on liver T cells and is improved by donor pretreatment with interleukin 10 in mice. Hepatology 2000; 31: 1266-1274.
29. Ellett JD, Atkinson C, Evans ZP etal. Murine Kupffer cells are protective in total hepatic ischemia/reperfusion injury with bowel congestion through IL-10. J. Immunol. 2010; 184: 5849-5858.
30. Feng M, Wang Q, Zhang F, Lu L. Ex vivo induced regulatory T cells regulate inflammatory response of Kupffer cells by tgf-beta and attenuate liver ischemia reperfusion injury. Int. Immunopharmacol. 2012; 12: 189-196.
31. Meng F, Wang K, Aoyama T etal. Interleukin-17 signaling in inflammatory, Kupffer, and hepatic stellate cells exacerbates liver fibrosis in mice. Gastroenterology 2012; 143: 765-776.
32. Wanner GA, Ertel W, Müller P etal. Liver ischemia and reperfusion induces a systemic inflammatory response through Kupffer cell activation. Shock 1996; 5: 34-40.
33. Hanschen M, Zahler S, Krombach F, Khandoga A. Reciprocal activation between CD4+ T cells and Kupffer cells during hepatic ischemia-reperfusion. Transplantation 2008; 86: 710-718.
34. Taniai H, Hines IN, Bharwani S etal. Susceptibility of murine periportal hepatocytes to hypoxia-reoxygenation: role for NO and Kupffer cell-derived oxidants. Hepatology 2004; 39: 1544-1552.
35. Kono H, Fujii H, Ogiku M etal. Role of IL-17A in neutrophil recruitment and hepatic injury after warm ischemia-reperfusion mice. J. Immunol. 2011; 187: 4818-4825.
36. Husted TL, Blanchard J, Schuster R, Shen H, Lentsch AB. Potential role for IL-23 in hepatic ischemia/reperfusion injury. Inflamm. Res. 2006; 55: 177-178.
37. Shibuya H, Ohkohchi N, Tsukamoto S, Satomi S. Tumor necrosis factor-induced, superoxide-mediated neutrophil accumulation in cold ischemic/reperfused rat liver. Hepatology 1997; 26: 113-120.
38. Xiang Z, Lv J, Jiang P, Chen C, Jiang B, Burnstock G. Expression of P2X receptors on immune cells in the rat liver during postnatal development. Histochem. Cell Biol. 2006; 126: 453-463.
39. Tsung A, Zheng N, Jeyabalan G etal. Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. J. Leukoc. Biol. 2007; 81: 119-128.
40. Loi P, Paulart F, Pajak B etal. The fate of dendritic cells in a mouse model of liver ischemia/reperfusion injury. Transplant. Proc. 2004; 36: 1275-1279.
41. Langrish CL, Chen Y, Blumenschein WM etal. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005; 201: 233-240.
42. Kuboki S, Sakai N, Tschöp J, Edwards MJ, Lentsch AB, Caldwell CC. Distinct contributions of CD4+ T cell subsets in hepatic ischemia/reperfusion injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2009; 296: G1054-1059.
43. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 2009; 31: 321-330.
44. Buonocore S, Ahern PP, Uhlig HH etal. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology. Nature 2010; 464: 1371-1375.
45. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying th17 responses and autoimmunity. Immunity 2009; 31: 331-341.
46. Uhlig HH, McKenzie BS, Hue S etal. Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity 2006; 25: 309-318.
47. Harrington LE, Hatton RD, Mangan PR etal. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005; 6: 1123-1132.
48. Korn T, Bettelli E, Gao W etal. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007; 448: 484-487.
49. Niedbala W, Wei XQ, Cai B etal. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of th17 cells. Eur. J. Immunol. 2007; 37: 3021-3029.
50. Zarember KA, Godowski PJ. Tissue expression of human toll-like receptors and differential regulation of toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 2002; 168: 554-561.
51. Zhai Y, Shen XD, Hancock WW etal. CXCR3+CD4+ T cells mediate innate immune function in the pathophysiology of liver ischemia/reperfusion injury. J. Immunol. 2006; 176: 6313-6322.
52. Zhai Y, Shen XD, Gao F etal. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology 2008; 47: 207-214.
53. Kawamura H, Aswad F, Minagawa M, Govindarajan S, Dennert G. P2X7 receptors regulate NKT cells in autoimmune hepatitis. J. Immunol. 2006; 176: 2152-2160.
54. Rachitskaya AV, Hansen AM, Horai R etal. Cutting edge: NKT cells constitutively express IL-23 receptor and rorgammat and rapidly produce IL-17 upon receptor ligation in an il-6-independent fashion. J. Immunol. 2008; 180: 5167-5171.
55. Lappas CM, Day YJ, Marshall MA, Engelhard VH, Linden J. Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting cd1d-dependent NKT cell activation. J. Exp. Med. 2006; 203: 2639-2648.
56. Lauzon NM, Mian F, MacKenzie R, Ashkar AA. The direct effects of toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell. Immunol. 2006; 241: 102-112.
57. Beldi G, Banz Y, Kroemer A etal. Deletion of CD39 on natural killer cells attenuates hepatic ischemia/reperfusion injury in mice. Hepatology 2010; 51: 1702-1711.
58. Feng M, Li G, Yuan Y etal. IL-17A-producing NK cells were implicated in liver injury induced by ischemia and reperfusion. Int. Immunopharmacol. 2012; 13: 135-140.
59. Tsung A, Klune JR, Zhang X etal. HMGB1 release induced by liver ischemia involves toll-like receptor 4 dependent reactive oxygen species production and calcium-mediated signaling. J. Exp. Med. 2007; 204: 2913-2923.
60. Bamboat ZM, Balachandran VP, Ocuin LM, Obaid H, Plitas G, Dematteo RP. Toll-like receptor 9 inhibition confers protection from liver ischemia-reperfusion injury. Hepatology 2009; 51: 621-632.
61. Liu S, Gallo DJ, Green AM etal. Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect. Immun. 2002; 70: 3433-3442.
62. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher DM. Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease. J. Clin. Pathol. 2007; 60: 415-418.
63. Sakai N, Van Sweringen HL, Quillin RC etal. Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice. Hepatology 2012; 56: 1468-1478.
64. Kuboki S, Sakai N, Clarke C etal. The peptidyl-prolyl isomerase, pin1, facilitates NF-kappab binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. J. Hepatol. 2009; 51: 296-306.
65. Colletti LM, Kunkel SL, Walz A etal. The role of cytokine networks in the local liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 1996; 23: 506-514.
66. Colletti LM, Green ME, Burdick MD, Strieter RM. The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/reperfusion in the rat. Hepatology 2000; 31: 435-445.
67. Lentsch AB, Yoshidome H, Kato A etal. Requirement for interleukin-12 in the pathogenesis of warm hepatic ischemia/reperfusion injury in mice. Hepatology 1999; 30: 1448-1453.
68. Yanagida H, Kaibori M, Yoshida H etal. Hepatic ischemia/reperfusion upregulates the susceptibility of hepatocytes to confer the induction of inducible nitric oxide synthase gene expression. Shock 2006; 26: 162-168.
69. Takeuchi D, Yoshidome H, Kato A etal. Interleukin 18 causes hepatic ischemia/reperfusion injury by suppressing anti-inflammatory cytokine expression in mice. Hepatology 2004; 39: 699-710.
70. Camargo CA, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. Hepatology 1997; 26: 1513-1520.
71. Kato A, Okaya T, Lentsch AB. Endogenous IL-13 protects hepatocytes and vascular endothelial cells during ischemia/reperfusion injury. Hepatology 2003; 37: 304-312.
72. Beldi G, Enjyoji K, Wu Y etal. The role of purinergic signaling in the liver and in transplantation: effects of extracellular nucleotides on hepatic graft vascular injury, rejection and metabolism. Front. Biosci. 2008; 13: 2588-2603.
73. Khandoga A, Hanschen M, Kessler JS, Krombach F. CD4+ T cells contribute to postischemic liver injury in mice by interacting with sinusoidal endothelium and platelets. Hepatology 2006; 43: 306-315.
74. Pignatelli P, Sanguigni V, Lenti L etal. Gp91phox-dependent expression of platelet CD40 ligand. Circulation 2004; 110: 1326-1329.
75. Seno T, Inoue N, Gao D etal. Involvement of NADH/NADPH oxidase in human platelet ROS production. Thromb. Res. 2001; 103: 399-409.
76. Marcus AJ, Silk ST, Safier LB, Ullman HL. Superoxide production and reducing activity in human platelets. J. Clin. Invest. 1977; 59: 149-158.
77. Collison KS, Parhar RS, Saleh SS etal. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (ages). J. Leukoc. Biol. 2002; 71: 433-444.
78. Li L, Huang L, Vergis AL etal. IL-17 produced by neutrophils regulates ifn-gamma-mediated neutrophil migration in mouse kidney ischemia-reperfusion injury. J. Clin. Invest. 2010; 120: 331-342.
79. Kimura H, Katsuramaki T, Isobe M etal. Role of inducible nitric oxide synthase in pig liver transplantation. J. Surg. Res. 2003; 111: 28-37.
80. Chen YX, Sato M, Kawachi K, Abe Y. Neutrophil-mediated liver injury during hepatic ischemia-reperfusion in rats. Hepatobiliary Pancreat. Dis. Int. 2006; 5: 436-442.
81. Colletti LM, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. Shock 1998; 10: 182-191.
82. Chestovich PJ, Uchida Y, Chang W etal. Interleukin-22: implications for liver ischemia-reperfusion injury. Transplantation 2012; 93: 485-492.
83. Serbina NV, Salazar-Mather TP, Biron CA, Kuziel WA, Pamer EG. TNF/iNOS-producing dendritic cells mediate innate immune defense against bacterial infection. Immunity 2003; 19: 59-70.
84. Cua DJ, Tato CM. Innate il-17-producing cells: the sentinels of the immune system. Nat. Rev. Immunol. 2010; 10: 479-489.
85. Zhu P, Duan L, Chen J etal. Gene silencing of NALP3 protects against liver ischemia-reperfusion injury in mice. Hum. Gene Ther. 2011; 22: 853-864.
86. Loi P, Yuan Q, Torres D etal. IRF3 deficiency leads to il-17-mediated liver ischemia-reperfusion injury. Hepatology 2012; doi: 10.1002/hep.26022.
87. Hirahara K, Ghoreschi K, Yang XP etal. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. Immunity 2012; 36: 1017-1030.
88. Zhai Y, Shen XD, O'Connell R etal. Cutting edge: TLR4 activation mediates liver ischemia/reperfusion inflammatory response via IFN regulatory factor 3-dependent myd88-independent pathway. J. Immunol. 2004; 173: 7115-7119.
89. Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat. Rev. Immunol. 2011; 11: 201-212.
90. Vaughn B, Robson SC, Burnstock G. Pathological roles of purinergic signaling in the liver. J. Hepatol. 2012; 57: 916-920.
91. Prime TA, Blaikie FH, Evans C etal. A mitochondria-targeted s-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 2009; 106: 10764-10769.
92. Ocuin LM, Zeng S, Cavnar MJ etal. Nilotinib protects the murine liver from ischemia/reperfusion injury. J. Hepatol. 2012; 57: 766-773.
93. Orrell RW. AEOL-10150 (Aeolus). Curr. Opin. Investig. Drugs 2006; 7: 70-80.
94. Deininger MW. Nilotinib. Clin. Cancer Res. 2008; 14: 4027-4031.
95. Smirnoff N, Cumbes QJ. Hydroxyl radical scavenging activity of compatible solutes. Phytochemistry 1989; 28: 1057-1060.
96. Miki M, Tamai H, Mino M, Yamamoto Y, Niki E. Free-radical chain oxidation of rat red blood cells by molecular oxygen and its inhibition by alpha-tocopherol. Arch. Biochem. Biophys. 1987; 258: 373-380.
97. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 1995; 19: 227-250.
98. Winterbourn CC. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 2008; 4: 278-286.
99. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003; 25: 295-311.
100. Fucci L, Oliver CN, Coon MJ, Stadtman ER. Inactivation of key metabolic enzymes by mixed-function oxidation reactions: possible implication in protein turnover and ageing. Proc. Natl. Acad. Sci. U.S.A. 1983; 80: 1521-1525.
101. Szabó C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat. Rev. Drug Discov. 2007; 6: 662-680.